↓ Skip to main content

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Overview of attention for article published in Cost Effectiveness and Resource Allocation, August 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Published in
Cost Effectiveness and Resource Allocation, August 2021
DOI 10.1186/s12962-021-00299-z
Pubmed ID
Authors

Mafalda Ramos, Peng Men, Xu Wang, Anastasia Ustyugova, Mark Lamotte

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 18%
Researcher 5 15%
Student > Bachelor 4 12%
Student > Ph. D. Student 3 9%
Lecturer 2 6%
Other 5 15%
Unknown 9 26%
Readers by discipline Count As %
Medicine and Dentistry 13 38%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Economics, Econometrics and Finance 2 6%
Nursing and Health Professions 2 6%
Unspecified 1 3%
Other 2 6%
Unknown 11 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2021.
All research outputs
#21,042,630
of 25,843,331 outputs
Outputs from Cost Effectiveness and Resource Allocation
#431
of 553 outputs
Outputs of similar age
#333,899
of 441,002 outputs
Outputs of similar age from Cost Effectiveness and Resource Allocation
#21
of 23 outputs
Altmetric has tracked 25,843,331 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 553 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,002 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.